PT  - JOURNAL ARTICLE
AU  - DANIEL ANSARI
AU  - HENRIK OHLSSON
AU  - CARL ALTHINI
AU  - MONIKA BAUDEN
AU  - QIMIN ZHOU
AU  - DINGYUAN HU
AU  - ROLAND ANDERSSON
TI  - The Hippo Signaling Pathway in Pancreatic Cancer
AID  - 10.21873/anticanres.13474
DP  - 2019 Jul 01
TA  - Anticancer Research
PG  - 3317--3321
VI  - 39
IP  - 7
4099  - http://ar.iiarjournals.org/content/39/7/3317.short
4100  - http://ar.iiarjournals.org/content/39/7/3317.full
SO  - Anticancer Res2019 Jul 01; 39
AB  - Hippo signaling is a key regulator of organ size, tissue hemostasis and regeneration. Dysregulation of the Hippo pathway has been recognized in a variety of human cancers, including pancreatic cancer. YES-associated protein (YAP) and transcriptional coactivator with PDZ-binding motif (TAZ) are the two major downstream effectors of the Hippo pathway. YAP and TAZ have been found to promote pancreatic tumor development and progression, even in the absence of mutant Kirsten RAS (KRAS). Pancreatic cancer is associated with an abundant stromal reaction leading to tumor growth and immune escape. It has been found that YAP and TAZ modulate behavior of pancreatic stellate cells and recruitment of tumor-associated macrophages and myeloid-derived suppressor cells. Moreover, YAP and TAZ are associated with chemoresistance and poor prognosis in pancreatic cancer. This review dissects the role of Hippo signaling in pancreatic cancer, focusing on molecular mechanisms and prospects for future intervention.